Dr Eleni Efstathiou (MD Anderson Cancer Center, Houston, USA) and Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) discuss the recent European approval of apalutamide for the treatment of metastatic hormone-sensitive prostate cancer at ASCO GU 2020 in San Francisco.
Prof Merseburger gives an overview of the TITAN trial and the results that supported the approval of apalutamide in this setting, including the evaluation of time to second progression (PFS2) in these patients - which was presented at this year’s meeting.
The panel discuss the clinical impact of this approval and how hormonal agents are prescribed in both Europe and North America, emphasising the need for improved education among healthcare professionals to use these therapies effectively.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
|Approval of apalutamide for the treatment of mHSPC|
|Clinical impact of apalutamide|
|Significance of PFS2|
|The use of hormonal agents in the US and EU|
|Safety profile of apalutamide|